23 Jul VectorY Therapeutics
Alexander Vos, CEO
VectorY Therapeutics is combining the power of gene therapy technology and antibodies to develop new therapies for neurodegenerative and muscle diseases. Founded in October 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody- and RNA-based targeted degradation technologies, and proprietary manufacturing technology. VectorY develops proprietary and partnered programs. Product candidates are based on new technologies that will enable the next generation of highly scalable manufacturing processes.